ETAO International Co., Ltd.

ETAO International Co., Ltd., a digital healthcare company, provides medical care and biomedical technologies to patients in China. It is involved in designing an ecosystem that consist of hospitals, specialized clinics, artificial intelligence/big data diagnosis, medical analysis services, biotechnology companies, and an insurance agency company that enables patient to receive medical assistance and healthcare services. The company is based in New York, New York.

ETAO International Co., Ltd. trades as ETAO on NASDAQ. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $58.06M of revenue and -$896.68M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

ETAO International Co., Ltd. can be compared against peers such as Apexigen, Inc., Cano Health, Inc., China Jo-Jo Drugstores, Inc., Centogene N.V., Cyclacel Pharmaceuticals, Inc., Field Trip Health Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $9.78M, beta of 1.92, and return on equity of +5748.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ETAO currently shows total debt of $15.41M and beta of 1.92. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 25-NSE (2025-08-06 00:00:00), SC 13G/A (2024-11-04 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.etao.world

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.